BR112021025806A2 - Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster - Google Patents

Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster

Info

Publication number
BR112021025806A2
BR112021025806A2 BR112021025806A BR112021025806A BR112021025806A2 BR 112021025806 A2 BR112021025806 A2 BR 112021025806A2 BR 112021025806 A BR112021025806 A BR 112021025806A BR 112021025806 A BR112021025806 A BR 112021025806A BR 112021025806 A2 BR112021025806 A2 BR 112021025806A2
Authority
BR
Brazil
Prior art keywords
human
nucleic acid
culturing
producing
cho cell
Prior art date
Application number
BR112021025806A
Other languages
English (en)
Portuguese (pt)
Inventor
Katharina Lutz
Stefan Klostermann
Stefan Seeber
Ulrich Goepfert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112021025806A2 publication Critical patent/BR112021025806A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021025806A 2019-06-28 2020-06-25 Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster BR112021025806A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19183171 2019-06-28
PCT/EP2020/067770 WO2020260431A1 (en) 2019-06-28 2020-06-25 Method for the production of an antibody

Publications (1)

Publication Number Publication Date
BR112021025806A2 true BR112021025806A2 (pt) 2022-02-08

Family

ID=67253661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025806A BR112021025806A2 (pt) 2019-06-28 2020-06-25 Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster

Country Status (11)

Country Link
US (1) US20220220500A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990484A1 (cg-RX-API-DMAC7.html)
JP (2) JP7511591B2 (cg-RX-API-DMAC7.html)
KR (1) KR102900433B1 (cg-RX-API-DMAC7.html)
CN (1) CN113993888B (cg-RX-API-DMAC7.html)
AU (1) AU2020304841B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025806A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143803A1 (cg-RX-API-DMAC7.html)
IL (1) IL289210A (cg-RX-API-DMAC7.html)
MX (1) MX2021015193A (cg-RX-API-DMAC7.html)
WO (1) WO2020260431A1 (cg-RX-API-DMAC7.html)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
JP2006238894A (ja) * 2000-02-15 2006-09-14 Amgen Inc 線維芽細胞成長因子−23分子およびその使用
ATE318908T1 (de) 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
WO2003070957A2 (en) 2002-02-20 2003-08-28 Novozymes A/S Plant polypeptide production
EP1490494A1 (en) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
KR20090018799A (ko) 2006-05-30 2009-02-23 다우 글로벌 테크놀로지스 인크. 코돈 최적화 방법
CA2657975A1 (en) 2006-06-29 2008-01-03 Dsm Ip Assets B.V. A method for achieving improved polypeptide expression
KR101163295B1 (ko) * 2007-06-29 2012-07-05 에프. 호프만-라 로슈 아게 향상된 면역글로불린을 생산하는 중쇄 돌연변이체
WO2009059235A2 (en) * 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
JP2012508563A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 抗IGF1R発現の増強のためのβGl−IGGイントロン
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids
KR20130013435A (ko) 2011-07-28 2013-02-06 차의과학대학교 산학협력단 태반-유래 줄기세포의 증식방법
RU2612910C2 (ru) * 2011-12-21 2017-03-13 Ф. Хоффманн-Ля Рош Аг Быстрый способ клонирования и экспрессии сегментов гена родственной вариабельной области антитела
CN107881196A (zh) * 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP6224077B2 (ja) * 2012-04-17 2017-11-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 改変された核酸を用いてポリペプチドを発現させるための方法
EA035266B1 (ru) * 2014-02-28 2020-05-22 Икнос Сайенсиз Са Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
KR20180018659A (ko) * 2015-06-08 2018-02-21 코닝 인코포레이티드 전달이 없는 마이크로엘이디 디스플레이

Also Published As

Publication number Publication date
IL289210A (en) 2022-02-01
US20220220500A1 (en) 2022-07-14
CN113993888B (zh) 2026-01-06
AU2020304841B2 (en) 2024-08-15
MX2021015193A (es) 2022-01-18
EP3990484A1 (en) 2022-05-04
JP2023183417A (ja) 2023-12-27
KR20220024954A (ko) 2022-03-03
CA3143803A1 (en) 2020-12-30
WO2020260431A1 (en) 2020-12-30
JP7835713B2 (ja) 2026-03-25
JP2022538178A (ja) 2022-08-31
JP7511591B2 (ja) 2024-07-05
CN113993888A (zh) 2022-01-28
AU2020304841A1 (en) 2021-12-23
KR102900433B1 (ko) 2025-12-15

Similar Documents

Publication Publication Date Title
BR112018006961A2 (pt) composição de fortalecimento para cabelos e método para fortalecer os cabelos
BR112018075688A2 (pt) anticorpos anti-c5 e métodos de uso
MX2021000934A (es) Linfocitos t que contienen nef y métodos para producirlos.
CY1123800T1 (el) Μεθοδος για την εκτελεση ενδο-προβλεψης χρησιμοποιωντας προσαρμοζομενο φιλτρο
BR112021019411A2 (pt) Métodos para a produção de células car-nk e uso das mesmas
HRP20200893T1 (hr) Pripravci stanične kulture s antioksidansima i postupci proizvodnje polipeptida
MX384138B (es) Anticuerpos anti-c5 y métodos para su uso.
BR112019011138A2 (pt) composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
NZ601743A (en) Methods for identifying and isolating cells expressing a polypeptide
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
BR112021014645A2 (pt) Método de edição de genes
BR112021024946A2 (pt) Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero
BR112013000515A2 (pt) método para prodduzir um composição de fator von willebrand recombinante (rvwf), sobrenadante de cultura de célula, e, composição do fator von willebrand recombinante (rvwf)
MX2014010021A (es) Anticuerpos biespecificos igg4 modificados de secuencia asimetrica.
MX2021003654A (es) Metodo para seleccionar neoepitopes.
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
WO2019108676A8 (en) Systems and methods of formal verification
EP3943065C0 (en) Composition of an injection formulation containing a mesenchymal stem cell hydrogel and its process of preparation, freezing and defrosting
MX2021001521A (es) Estrategias de cultivo celular para modular la glucosilacion de proteinas.
BR112021020867A2 (pt) Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
BR112017018704A2 (pt) métodos para produção de células troncos neurais e usos das mesmas
BR112021020357A2 (pt) Anticorpos anti-cd3 de alta afinidade e métodos para sua geração e uso
MX2020012649A (es) Neoantígenos especificos de tumor y métodos de uso de estos.
BR112022003852A2 (pt) Métodos de preparação de células t para terapia de células t
D’Agostino et al. Potential of biofermentative unsulfated chondroitin and hyaluronic acid in dermal repair

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]